Skip to main content

Home/ Dr. Goodyear/ Group items tagged ki-67

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Ki-67 is a prognostic parameter in breast cancer patients: results of a large populatio... - 0 views

www.ncbi.nlm.nih.gov/...PMC3669503

ki-67 cancer breast cancer

shared by Nathan Goodyear on 06 Sep 18 - No Cached
  • A wide range of techniques is available to assess tumor cell proliferation such as calculating mitotic figures in stained tissue segments, flow cytometric analysis to determine the proportion of cells being in the S phase of the cell cycle, examination of thymidine-labeling index, proliferating cell nuclear antigen (PCNA), or cyclins E and D
  • Ki-67 is a nuclear protein being associated with cellular proliferation and was originally identified by Gerdes et al.
  • Ki-67 nuclear antigen is expressed in certain phases of the cell cycle namely S, G1, G2, and M phases, but is nonexisting in G0
  • ...11 more annotations...
  • Ki-67 is also expressed at low levels (<3 % of cells) in ER-negative cells, but not in ER-positive cells
  • A meta-analysis involving 12,155 patients demonstrated that the Ki-67 positivity confers a higher risk of recurrence and a worse survival rate in patients with early breast cancer.
  • high levels of Ki-67 are associated with worse prognoses
  • Ki-67 was associated with worse survival rates
  • associated with proliferation
  • higher tumor stages and higher nodal status were associated with higher Ki-67 quartiles indicating that the more aggressive the tumor is the higher is the percentage of cells positively stained for Ki-67
  • Previous studies were able to demonstrate that a prognostic model, the IHC 4 score, using ER, PR, HER2, and Ki-67 provides similar prognostic information to that in the 21-gene Genomic Health recurrence score
  • ER status has been largely identified as being inversely correlated with Ki-67, with the higher rates of ER positivity shown in the lowest proliferating tumors
  • high levels of Ki-67 are associated with HER2/-neu positivity according to former studies
  • higher values of Ki-67-labeling index were associated with adverse prognostic factors
  • Ki-67-labeling index was associated with larger tumors, higher tumor grade, peritumoral vascular invasion, and HER-2 positivity
  • Nathan Goodyear on 06 Sep 18
     
     Increased disease free survival and overall survival in people with breast cancer with ki-67 <15%
Nathan Goodyear

Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast can... - 0 views

www.nature.com/...bjc2014207

PET scan PET_CT scan cancer breast

shared by Nathan Goodyear on 19 Mar 18 - No Cached
  • We have demonstrated that the majority of patients have a sizeable reduction in SUVmax from a single cycle of NAC with a mean change of −32.3%
  • This study, however, failed to show any predictive markers of response after one cycle of chemotherapy
  • These data therefore suggest that the main utility of FLT-PET as an imaging biomarker in early breast cancer is pre-chemotherapy, as a marker of proliferation, rather than in predicting pathological response after chemotherapy
  • ...2 more annotations...
  • In terms of the histological proliferation biomarker Ki-67, we have shown a good correlation with FLT-PET pre-chemotherapy. The best predictive marker of response in terms of pCR was baseline Ki-67
  • Our study has shown that baseline Ki-67 and FLT SUVmax is well correlated in keeping with FLT-PETs status as a proliferation biomarker, although Ki-67 had a better predictive ability in terms of pathological outcome
  • Nathan Goodyear on 19 Mar 18
     
    PET CT scan shown to be useful as a proliferation biomarker pre-chemo in breast cancer.
Nathan Goodyear

First Study of Oral Artenimol-R in Advanced Cervical Cancer: Clinical Benefit, Tolerabi... - 0 views

ar.iiarjournals.org/...4417.long

artemisinin EGFR artesunate Ki67 p53 CD31 cervical cancer

shared by Nathan Goodyear on 13 Jun 19 - No Cached
  • Nathan Goodyear on 13 Jun 19
     
    Results show a clear down-regulation of p53, EGFR, Ki-67 and CD31 in cervical cancer cells.
Nathan Goodyear

Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignan... - 0 views

www.ncbi.nlm.nih.gov/...PMC3665464

TK-1 TK-1 cancer thymidine kinase 1 cancer biomarker

shared by Nathan Goodyear on 04 Mar 15 - No Cached
  • Thymidine kinase 1 (TK1) is a proliferation biomarker
  • Nuclear TK1 expression in early grade CIN predicts risk for progression to malignancy
  • Nuclear TK1 expression is also a prognostic factor for treatment outcome
  • ...9 more annotations...
  • TK1 LI was found to be a more reliable prognostic marker for 5-year survival than pathological stages, FIGO stages and Ki-67,
  • nuclear TK1 expression is a reliable prognostic factor in CIN patients, a group of cervical lesion patients that respond positively to treatment
  • nuclear TK1 expression is correlated with advanced stage of invasive cervical carcinomas
  • a low TK1 LI can help to identify with a better survival
  • low TK1 expression in the tumors in these patients might indicate that these tumors have a lower proliferation rate
  • TK1 is a key kinase in the one-step salvage pathway by which thymidine is introduced into DNA via the salvage pathway
  • TK1 participates in DNA synthesis and is therefore closely related to the S-phase of the cell cycle, and is correlated with proliferation
  • TK1 intensity (TK1 synthesis rate) increases from CIN grade I to CIN grade III, but does not further increase in invasive cervical carcinomas.
  • TK1 intensity seems to be a prognostic factor particularly when pre-malignant cervical lesions progress to malignancy
  • Nathan Goodyear on 04 Mar 15
     
    TK-1 is a proliferation biomarker of DNA repair. TK-1 is a nuclear biomarker of cancer prognosis, survival, recurrence and predicts risk of progression of pre-malignant disease.
Nathan Goodyear

Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomog... - 0 views

www.ncbi.nlm.nih.gov/...PMC3785187

PET scan PET_CT scan maxSUV cancer breast

shared by Nathan Goodyear on 19 Mar 18 - No Cached
  • 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is an effective and popular technique for evaluating patients before and after breast cancer surgery.
  • Quantitative FDG-PET/CT imaging is becoming prevalent in cancer treatment as it measures glucose metabolism that reflects the growth potential and metabolic activity of malignant tumors
  • The FDG-PET/CT findings of primary lesions in colorectal and lung cancers correlate with metastasis and prognosis because FDG reflects tumor viability
  • ...15 more annotations...
  • The technique is valuable for predicting the prognosis of patients with recurrent breast cancer and for determining and predicting the outcomes of neoadjuvant chemotherapy
  • FDG-PET/CT is useful not only for evaluating metastasis but also for predicting the prognosis of recurrent breast cancer and measuring treatment effects
  • reports remain limited to small-scale clinical trials of about 100 patients.
  • MaxSUV, which is the most popular FDG-PET/CT value, can vary up to 30&nbsp;% because of differences among PET/CT devices and among the operators who create the images
  • the degree of malignancy would increase with an increase in maxSUV when ER or HER-2 signaling is involved.
  • Factors that determine the rate of cancer progression include T-factor (tumor diameter) and N-factor (presence or absence/number of lymph node metastasis)
  • The prognostic factors applied in breast cancer can be broadly divided into those that determine staging and those that determine biological tumor characteristics
  • Prognosis was previously predicted based on T, N, and M staging, which indicates the degree of progression. However, prognosis is now predicted and treatment regimes are presently selected by also considering ER and HER-2 levels, which determine the nature of the tumor
  • maxSUV presently serves as an indicator of metabolic activity during cancer therapy. For instance, the maxSUV of primary lung and hematological cancer lesions correlates with metastasis and prognosis, whereas maxSUV also seems useful for predicting the prognosis of recurrent breast cancer and in determining and predicting the outcome of neoadjuvant chemotherapy
  • The maxSUV cut-off calculated from ROC curves for recurrence was 3.0
  • Factors that determine the nature of tumors also include ER, HER-2, Ki-67 labeling index, and nuclear grade
  • both ER status and maxSUV as independent prognostic factors
  • maxSUV has a closer correlation with prognosis
  • maxSUV, clinical T-factor and ER were significant prognostic factors
  • Our results showed that maxSUV has the potential to be a novel prognostic factor and that it can be used to determine future therapies
  • Nathan Goodyear on 19 Mar 18
     
    Retrospective, multi-facility finds maxSUV can be used in prognosis in cancer.  Others have shown benefit in recurrence risk.  MaxSUV was found to be an independent factor.
1 - 5 of 5
Showing 20▼ items per page